Seaport's GlyphAllo Shows No Driving Impairment in Phase 1, Boosting MDD Program
SPTX sits 55% above its 52-week low of $14.85.
Summary
Seaport Therapeutics reported positive topline results from its Phase 1 Driving Simulation Trial of GlyphAllo, an oral prodrug of allopregnanolone for major depressive disorder. The trial met its primary endpoint: evening dosing of 375 mg did not impair next-morning driving performance versus placebo on Day 5. A key secondary endpoint also showed no impairment with a single 250 mg dose on Day 2. No serious adverse events were reported. These results support the safety profile of GlyphAllo and its differentiation from other allopregnanolone-based therapies, which can cause sedation. The company plans to submit the data to the FDA as part of its ongoing development program. This follows the Q2 2026 report showing $427.3 million in cash, funding operations into 2029. The next major catalyst is topline data from the Phase 2b BUOY-1 trial in MDD, expected in the first half of 2027.
At the time of this announcement, SPTX was trading at $22.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $14.85 to $28.38. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.